KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gross Profit (2020 - 2023)

Historic Gross Profit for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to $6.1 million.

  • AbCellera Biologics' Gross Profit fell 6961.87% to $6.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $23.8 million, marking a year-over-year decrease of 9430.89%. This contributed to the annual value of $16.1 million for FY2024, which is 3267.35% down from last year.
  • Per AbCellera Biologics' latest filing, its Gross Profit stood at $6.1 million for Q4 2023, which was down 6961.87% from $3.1 million recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Gross Profit ranged from a high of $271.9 million in Q1 2022 and a low of $3.1 million during Q3 2023
  • Its 4-year average for Gross Profit is $61.1 million, with a median of $15.3 million in 2020.
  • In the last 5 years, AbCellera Biologics' Gross Profit surged by 423011.85% in 2021 and then tumbled by 9690.34% in 2023.
  • Over the past 4 years, AbCellera Biologics' Gross Profit (Quarter) stood at $182.4 million in 2020, then crashed by 35.61% to $117.4 million in 2021, then crashed by 82.96% to $20.0 million in 2022, then tumbled by 69.62% to $6.1 million in 2023.
  • Its Gross Profit stands at $6.1 million for Q4 2023, versus $3.1 million for Q3 2023 and $6.2 million for Q2 2023.